Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abraxis BioScience, Inc.
Abraxis BioScience Appoints David O'Toole as Chief Financial Officer
June 13th, 2008
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global biotechnology company, announced that David O'Toole has been appointed Executive Vice President and Chief Financial Officer, succeeding Lisa Gopala. Mr. O'Toole, 49, comes to Abraxis with 24 years of experience providing financial, consulting and international tax services to global companies, with particular expertise in the life sciences industry. Mr. O'Toole was with Deloitte & Touche LLP for the past 16 years, last serving as Partner - Strategic Client Group, where he was responsible for providing solutions to issues facing the life sciences industry for biotechnology clients such as Amgen, including...
Source: Health Business Week (2008-06-13)
|
